Tags

Type your tag names separated by a space and hit enter

Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study.
Int J Clin Exp Med 2012; 5(3):238-44IJ

Abstract

AIM

To investigate the effect of bifid triple viable capsule, a multistrain probiotic preparation on symptoms of irritable bowel syndrome (IBS), and the amount of fecal Bifidobacterium spp. and Lactobacillus spp. of IBS patients before and after treatment.

METHODS

A total of 60 IBS patients who met Rome III criteria were included in this double-blind, randomized, and placebo-controlled study. The patients were randomly assigned to receive composite probiotics or placebo for four weeks. The IBS symptoms of participants were surveyed using a questionnaire, and the amount of fecal Bifidobacterium spp. and Lactobacillus spp. was determined by quantitative Real-time PCR pre- and post-intervention.

RESULTS

During the four week intervention period, the patients receiving probiotic preparation showed a significantly greater improvement in the symptom severity score of IBS, severity and frequency of pain or discomfort, abdominal distention and satisfaction with bowel habits. The symptom subtypes revealed that low amounts of both Bifidobacterium spp. and Lactobacillus spp. were present in the samples of diarrhea-predominant IBS patients, while the alternating-predominant IBS patients had only low amounts of Bifidobacterium spp. Post-intervention for diarrhea-predominant IBS patients with lower symptom severity score showed even lower amounts of Bifidobacterium spp. and Lactobacillus spp.

CONCLUSION

Bifid triple viable capsule supplement may benefit patients with IBS. Multistrain probiotic preparation may be a promising candidate for IBS therapy, although the mechanism needs to be further studied.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22837798

Citation

Cui, Shusheng, and Ying Hu. "Multistrain Probiotic Preparation Significantly Reduces Symptoms of Irritable Bowel Syndrome in a Double-blind Placebo-controlled Study." International Journal of Clinical and Experimental Medicine, vol. 5, no. 3, 2012, pp. 238-44.
Cui S, Hu Y. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Int J Clin Exp Med. 2012;5(3):238-44.
Cui, S., & Hu, Y. (2012). Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. International Journal of Clinical and Experimental Medicine, 5(3), pp. 238-44.
Cui S, Hu Y. Multistrain Probiotic Preparation Significantly Reduces Symptoms of Irritable Bowel Syndrome in a Double-blind Placebo-controlled Study. Int J Clin Exp Med. 2012;5(3):238-44. PubMed PMID: 22837798.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. AU - Cui,Shusheng, AU - Hu,Ying, Y1 - 2012/06/16/ PY - 2011/11/25/received PY - 2012/04/28/accepted PY - 2012/7/28/entrez PY - 2012/7/28/pubmed PY - 2012/7/28/medline KW - Irritable bowel syndrome KW - gut microbiota KW - probiotics KW - real-time PCR SP - 238 EP - 44 JF - International journal of clinical and experimental medicine JO - Int J Clin Exp Med VL - 5 IS - 3 N2 - AIM: To investigate the effect of bifid triple viable capsule, a multistrain probiotic preparation on symptoms of irritable bowel syndrome (IBS), and the amount of fecal Bifidobacterium spp. and Lactobacillus spp. of IBS patients before and after treatment. METHODS: A total of 60 IBS patients who met Rome III criteria were included in this double-blind, randomized, and placebo-controlled study. The patients were randomly assigned to receive composite probiotics or placebo for four weeks. The IBS symptoms of participants were surveyed using a questionnaire, and the amount of fecal Bifidobacterium spp. and Lactobacillus spp. was determined by quantitative Real-time PCR pre- and post-intervention. RESULTS: During the four week intervention period, the patients receiving probiotic preparation showed a significantly greater improvement in the symptom severity score of IBS, severity and frequency of pain or discomfort, abdominal distention and satisfaction with bowel habits. The symptom subtypes revealed that low amounts of both Bifidobacterium spp. and Lactobacillus spp. were present in the samples of diarrhea-predominant IBS patients, while the alternating-predominant IBS patients had only low amounts of Bifidobacterium spp. Post-intervention for diarrhea-predominant IBS patients with lower symptom severity score showed even lower amounts of Bifidobacterium spp. and Lactobacillus spp. CONCLUSION: Bifid triple viable capsule supplement may benefit patients with IBS. Multistrain probiotic preparation may be a promising candidate for IBS therapy, although the mechanism needs to be further studied. SN - 1940-5901 UR - https://www.unboundmedicine.com/medline/citation/22837798/Multistrain_probiotic_preparation_significantly_reduces_symptoms_of_irritable_bowel_syndrome_in_a_double_blind_placebo_controlled_study_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22837798/ DB - PRIME DP - Unbound Medicine ER -